Masterflex SE has achieved its forecast for the 2025 financial year according to preliminary figures, posting new record earnings while strengthening its financial position. The company reported consolidated revenue of EUR 102.6 million, exceeding the previous year's level of EUR 98.1 million by 4.6% and falling within the forecast range of EUR 100 million to EUR 105 million. This performance is significant as it demonstrates the company's ability to deliver growth despite persistent economic challenges that have particularly affected the German market.
The company's operational performance developed positively, with the US subgroup performing particularly well in 2025. The medical technology area experienced dynamic demand growth, increasing its share of consolidated revenue from 18% in 2024 to 21% in 2025. This shift toward higher-margin medical technology business represents an important strategic development for Masterflex's future profitability. Despite economic headwinds, demand in industrial customer sectors grouped under "Tech" and in the trading business declined only moderately, and the order backlog remained stable at EUR 19.8 million at year-end.
Masterflex achieved record earnings with operating EBITDA rising 7.4% to EUR 19.5 million and operating EBIT increasing 9.8% to EUR 14.0 million. The operating EBIT margin improved to 13.6% from 13.0% in the previous year, despite currency losses and start-up costs for the new site in Morocco. EBIT reached EUR 13.7 million, within the forecast range of EUR 12 million to EUR 15 million. These results matter because they show sustained earnings strength and operational efficiency improvements even while expanding international operations.
The company significantly strengthened its financial position, with the equity ratio improving to 73.3% from 67.7% in the previous year. Financial liabilities were substantially reduced, with net debt falling to EUR 2.7 million from EUR 9.0 million. The debt ratio improved to 0.1 from 0.5, indicating a much stronger balance sheet. This financial improvement is crucial as it provides Masterflex with greater stability and flexibility for future investments and growth initiatives.
Dr. Andreas Bastin, CEO of Masterflex SE, commented on the results through the company's investor relations contact at www.crossalliance.de, stating that despite the challenging environment, the company met forecasts, achieved solid revenue growth, and slightly increased profitability through continuous efficiency improvements. He noted particular satisfaction with the development of the medical technology business and further strengthening of the balance sheet, positioning the company well to continue its growth course in coming years.
The figures remain subject to confirmation by auditors and approval by the Supervisory Board, with the 2025 consolidated financial statements and 2026 forecast scheduled for publication on March 31, 2026. The original release can be viewed on www.newmediawire.com. Masterflex's performance demonstrates how specialized manufacturing companies can achieve growth and improved financial health through strategic focus on higher-margin segments and international expansion, even during economically challenging periods.
